Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 219

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 219
---

of Designations contains standard and customary triggering events (each, a “Series E Triggering Event”), including but not
limited to: (i) the suspension from trading or the failure to list the Common Stock within certain time periods; (ii) failure to declare
or pay any dividend when due; (iii) the failure to timely file or make effective a registration statement on Form S-1 or Form S-3 pursuant
to the Registration Rights Agreement (as defined below), (iv) the Company’s failure to cure a conversion failure or notice of the
Company’s intention not to comply with a request for conversion of any Series E Preferred Stock, and (iv) bankruptcy or insolvency
of the Company.

Other Adjustments.
In connection with the Private Placement, the Company has agreed to seek stockholder approval at a special meeting of stockholders, of
the issuance of Conversion Shares at a conversion price below the Series E Conversion Price (the date of such approval, the “Series
E Stockholder Approval Date”). If the Company has not otherwise obtained such stockholder approval prior to October 31, 2025, which
is not expected to occur, then the Company shall (i) file a preliminary Proxy Statement seeking such stockholder consent with the SEC
no later than October 31, 2025, (ii) use reasonable best efforts to file the definitive Proxy Statement no later than November 30, 2025
and (iii) use reasonable best efforts to hold the Stockholder Meeting no later than December 31, 2025 (the “Stockholder Meeting
Deadline”). If, on or after the Series E Stockholder Approval Date, the Company issues any shares of Common Stock for a consideration
per share (the “New Issuance Price”) less than a price equal to the Series E Conversion Price in effect immediately prior
to such issuance (each, a “Dilutive Issuance”), the Series E Conversion Price shall be reduced to the New Issuance Price;
provided that, if any Dilutive Issuances or other events that would have resulted in an adjustment to the Series E Conversion Price prior
to the Series E Stockholder Approval Date, the Series E Conversion Price shall automatically adjust to such New Issuance Price on the
Series E Stockholder Approval Date.

Bankruptcy Triggering
Event Redemption Right. Upon any bankruptcy Series E Triggering Event, the Company shall immediately redeem in cash all amounts due
under the Series E Preferred Stock at a 25% premium